Rakesh Jain, MD, MPH will review the latest data on current and recently approved treatments for tardive dyskinesia (TD) and how to incorporate that information into everyday clinical practice through interactive case discussions.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Describe the underlying biologic mehanisms that link the prevalence and risk of developing TD to the use of antipsychotic medication
- Identify the signs and symptoms of TD to facilitate the appropriate referral of patients for specialty care
- Evaluate current approaches to TD management, both traditional methods and newer pharmacotherapies, with respect to their clinical efficacy, safety, and indications
NPs and PAs
There are no prerequisites to participate in this activity.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Practicing Clinicians Exchange (PCE). NACCME is is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.
This continuing nursing education activity awards 1 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.
Independent Clinical Reviewer: William C. Torrey, MD, Professor of Psychiatry, Dartmouth’s Geisel School of Medicine, Hanover, New Hampshire; Associate Psychiatry, Service Line Leader, Dartmouth-Hitchcock, Lebanon, New Hampshire
Nurse Planner: Andrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, California; Assistant Clinical Professor, University of California, San Francisco, California
The planning committee comprises Rakesh Jain, MD, MPH; Susan M. Tiso, DNP, APRN, FNP-BC; William C. Torrey, MD; Andrew Penn, RN, MS, NP, CNS, APRN-BC; and Meaghan Benci, Kelly Sweeney, Jennifer Ilcyn, Randy Robbin, and Susan Yarbrough, NACCME.
This program was cosupported by educational grants from Amgen; Astellas; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Genentech; Gilead Sciences, Inc.; Neurocrine Biosciences and Teva Pharmaceuticals; Sanofi US; Shire; and Sunovion Pharmaceuticals, Inc.
This activity is supported by an educational grant from Neurocrine Biosciences and Teva Pharmaceuticals.
NACCME and PCE protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME and PCE maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2018 North American Center for Continuing Medical Education LLC and Practicing Clinicians Exchange. All Rights Reserved.
No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education or Practicing Clinicans Exchange. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or PCE. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr Jain: advisory board: Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; consultant: Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; consultant (spouse): Lilly, Otsuka, Pamlab, Sunovion; grant/research support: AstraZeneca, Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; speakers bureau: Addrenex, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, Tris.
Dr Tiso, Dr Torrey, Mr Penn, Ms Benci, Ms Sweeney, Ms Ilcyn, Mr Robbin, and Ms Yarbrough have no relevant financial relationships to disclose.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty have disclosed that no off-label/unapproved uses of drugs and/or devises will be discussed in the presentations.
Participants wishing to earn CE/CME credit must:
- Review the eCourse activity
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete each activity is 1 hour.
Release date: October 31, 2018
Expiration date: October 30, 2019
Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+
© 2018 Practicing Clinicians Exchange. All Rights Reserved. CPCE93218-7I